|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
HYALURONIDASE EFFECT IS INHIBITED BY THE DRUG
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS DIPYRIDAMOLE , MAY INCREASE THE RISK OF BLEEDING
|
DESMOPRESSIN ANTIDIURETIC EFFECT IS REDUCED BY THE DRUG
|
PENICILLINS IN HIGH DOSES MAY AFFECT THE COAGULATION PROCESS AND MAY CAUSE INCREASED BLEEDING WHEN CONCURRENTLY USED
|
PENICILLINS IN HIGH DOSES MAY AFFECT THE COAGULATION PROCESS AND MAY CAUSE INCREASED BLEEDING WHEN CONCURRENTLY USED
|
PENICILLINS IN HIGH DOSES MAY AFFECT THE COAGULATION PROCESS AND MAY CAUSE INCREASED BLEEDING WHEN CONCURRENTLY USED
|
PENICILLINS IN HIGH DOSES MAY AFFECT THE COAGULATION PROCESS AND MAY CAUSE INCREASED BLEEDING WHEN CONCURRENTLY USED
|
PENICILLINS IN HIGH DOSES MAY AFFECT THE COAGULATION PROCESS AND MAY CAUSE INCREASED BLEEDING WHEN CONCURRENTLY USED
|
PENICILLINS IN HIGH DOSES MAY AFFECT THE COAGULATION PROCESS AND MAY CAUSE INCREASED BLEEDING WHEN CONCURRENTLY USED
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH ORAL ANTICOAGULANTS MAY INCREASE THE RISK OF BLEEDING
|
DRUGS THAT ALTER PLATELET FUCNCTION, SUCH AS TICLOPIDINE , MAY INCREASE THE RISK OF BLEEDING
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
VASOPRESSIN ANTIDIURETIC EFFECT IS REDUCED
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
CO-ADMINISTRATION SHOULD BE UNDERTAKEN WITH CAUTION ; CONCOMITANT HEPARIN HAS NO EFFECT ON INHIBITION OF PLATELET AGGREGATION INDUCED BY CLOPIDOGREL
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|